CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Revenues:
Finance receivable interest income, including fees	$ 40,787	$ 36,346
Pharmaceutical development	3,616	1,202
Other	584	212
Total revenues	44,987	37,760
Costs and expenses:
Provision for credit losses	12,756	1,912
Loss on impairment of intangible assets	5,771	0
Impairment of goodwill	0	8,404
Interest expense	4,685	1,849
Pharmaceutical manufacturing, research and development expense	2,203	3,436
Change in fair value of acquisition-related contingent consideration	(4,900)	(6,300)
Depreciation and amortization expense	1,399	2,577
General and administrative expense	11,487	11,232
Income from operations	11,586	14,650
Other income (expense), net
Unrealized net gain (loss) on warrants	2,406	(55)
Net gain (loss) on exercise and cancellation of warrants	445	(799)
Net loss on marketable investments	(266)	0
Realized gain on early payment of finance receivable	1,065	0
Gain on revaluation of finance receivable	2,495	0
Realized and unrealized foreign currency transaction gains	641	817
Income before income tax expense (benefit)	18,372	14,613
Income tax expense (benefit)	4,884	(1,274)
Net income	$ 13,488	$ 15,887
Net income per share
Basic (in dollars per share)	$ 1.09	$ 1.26
Diluted (in dollars per share)	$ 1.08	$ 1.25
Weighted average shares outstanding
Basic (in shares)	12,369	12,653
Diluted (in shares)	12,451	12,696